- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01488578
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) (POTTOR)
January 26, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.
Study Overview
Detailed Description
All the subjects whom an investigator prescribes the first Detrusitol Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study Type
Observational
Enrollment (Actual)
11157
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The subjects whom an investigator involving A6121186 prescribes the Tolterodine tartrate (Detrusitol Capsule).
Description
Inclusion Criteria:
- Male or female subjects intend to treat their overactive bladder who are prescribed Detrusitol Capsule by their physicians.
Exclusion Criteria:
- Subjects who have been prescribed Detrusitol Capsule before.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Tolterodine tartrate.
Subjects taking Tolterodine tartrate.
|
Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs).
Time Frame: 12 weeks
|
All observed or volunteered adverse events and the investigator's opinion of the causal relationship to the study treatment were reported.
Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates.
Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.
|
12 weeks
|
Number of Participants Which Was Evaluated as "Degree of Satisfaction".
Time Frame: 12 week
|
Participant satisfaction was evaluated by investigators based on questioning the participants at the end of observation period using choices: Satisfied, Dissatisfied, Neither of the above.
|
12 week
|
Number of Participants With an Investigator's Assessment of Clinical Outcome at End of the Study.
Time Frame: 12 week
|
Clinical overall effectiveness was evaluated by investigators based on clinical symptoms, etc, at the end of observation period.
|
12 week
|
Confirmation of Frequent Treatment Related Adverse Events (TRAEs) at the End of Observation Period.
Time Frame: 12 week
|
The Treatment Related Adverse Events (TRAEs) at the end of observation period with an incidence of 1% or higher.
|
12 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether with or without concomitant drugs is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether with or without Non-drug therapies is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Gender
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether male or female is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Complications
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether with or without complications is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Age
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether <65 years or >=65 years is significant risk factor.
|
12 week
|
Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy
Time Frame: 12 week
|
Number of participants with Treatment Related Adverse Events (TRAEs) of tolterodine to determine whether with or without comorbidity of benign prostatic hypertrophy (BPH) is significant risk factor.
|
12 week
|
Number of Unlisted Treatment Related Adverse Events (TRAEs)Reported in at Least 5 Participants
Time Frame: 12 week
|
All observed or volunteered adverse events and the investigator's opinion of the causal relationship to the study treatment were reported.
Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates.
Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.
Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Severity of Overactive Bladder
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether mild, moderate or severe is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine whether with or without Urinary urgency is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinations Per Day (During Sleep)
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine the Number of urinations per day (during sleep) is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinary Incontinence Episodes Per Day
Time Frame: 12 week
|
Number of participants with responders of tolterodine to determine the Number of urinary incontinence episodes per day is significant risk factor.
|
12 week
|
Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment
Time Frame: 12 week
|
Number of participants with response to tolterodine to determine whether with or without previous treatment is significant risk factor.
|
12 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
April 27, 2011
First Submitted That Met QC Criteria
December 6, 2011
First Posted (Estimate)
December 8, 2011
Study Record Updates
Last Update Posted (Actual)
January 28, 2021
Last Update Submitted That Met QC Criteria
January 26, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Tolterodine Tartrate
Other Study ID Numbers
- A6121186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Tolterodine tartrate
-
Merck Sharp & Dohme LLCCompleted
-
Peking University People's HospitalUnknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Urovant Sciences GmbHCompletedOveractive BladderUnited States, Latvia, Hungary, Canada, Lithuania, Poland
-
PfizerCompletedUrinary Bladder, Overactive
-
Shanghai Institute of Acupuncture, Moxibustion...RenJi HospitalCompletedUrgency-frequency SyndromeChina
-
PfizerCompletedOveractive BladderDenmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
-
KYU-SUNG LEEPfizerCompletedOveractive BladderKorea, Republic of
-
Mayo ClinicPfizerCompleted
-
Yuzuncu Yıl UniversityCompletedOveractive Bladder | Obstructive Sleep Apnea | Overactive Bladder SyndromeTurkey